Document is current
Any future updates will be listed below
-
Authors
Shah, R. http://orcid.org/0000-0001-8158-712X
Finlay, A.Y. http://orcid.org/0000-0003-2143-1646
Salek, M.S. http://orcid.org/0000-0002-4612-5699
Allen, H.
Nixon, S.J.
Nixon, M.
Otwombe, K. http://orcid.org/0000-0002-7433-4383
Ali, F.M. http://orcid.org/0000-0002-4184-2023
Ingram, J.R. http://orcid.org/0000-0002-5257-1142
- License Information
-
More Information
Article History
Received: 15 June 2023
Accepted: 15 February 2024
First Online: 26 March 2024
Declarations
:
: The study was approved by the Health Research Authority (HRA) and Health and Care Research Wales (HCRW) 20/EE/0242. All patients and family members gave their electronic informed consent.
: Not applicable.
: RS, KO, HA, MN and SJN declared no competing interest; FMA is employed by Cardiff University: Cardiff University receives royalties from some uses of FROM-16; AYF reports personal fees from Novartis Lecture honorarium, personal fees from Medscape Podcast honorarium, personal fees from Eli Lilly Lecture honorarium, outside the submitted work; MSS and AYF are joint copyright owner of the FROM-16 for which Cardiff University receives royalties for its commercial use, and they receive a share under standard university policy. JRI receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. He is a consultant for Abbvie, Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis and UCB Pharma and has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio. He is co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for HS. His department receives income from royalties for the use of the Dermatology Life Quality Index (DLQI), Family Reported Outcome Measure (FROM-16) and related instruments.
